CIK 0001671858
- Non-accelerated filer
- Smaller reporting company
ARS Pharmaceuticals, Inc.
Sign in to watch- Ticker
- SPRY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 811489190
- Phone
- +1 858-771-9307
- Business address
- 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Silverback Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-08-26 | ORBIMED ADVISORS LLC Director | Sale | −83,695 | $13.00 | $1.1M | 0 |
| 2024-08-23 | ORBIMED ADVISORS LLC Director | Sale | −69,500 | $13.03 | $906K | 83,695 |
| 2024-08-22 | ORBIMED ADVISORS LLC Director | Sale | −391,482 | $12.94 | $5.1M | 153,195 |
| 2024-08-21 | ORBIMED ADVISORS LLC Director | Sale | −394,400 | $13.52 | $5.3M | 557,977 |
| 2024-08-21 | ORBIMED ADVISORS LLC Director | Sale | −13,300 | $14.61 | $194K | 544,677 |
| 2023-08-29 | ORBIMED ADVISORS LLC Director | Purchase | +500,000 | $6.20 | $3.1M | 8,019,187 |
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Purchase | +238,100 | $21.00 | $5.0M | 507,423 |
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +3,462,737 | 3,970,160 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +2,493,741 | 6,463,901 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion | +1,055,287 | 7,519,188 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Purchase | +952,377 | $21.00 | $20.0M | 952,377 |
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series A Preferred Stock | −12,857,142 | 0 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series B Preferred Stock | −9,259,259 | 0 | ||
| 2020-12-08 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −3,918,279 | 0 |
Page 1 of 1 · 14 trades